Can optimal acid suppression prevent rebleeding in peptic ulcer patients with a non-bleeding visible vessel: A preliminary report of a randomized comparative study

Hwai Jeng Lin, Wen Ching Lo, Chin Lin Perng, Kun Wang, Fa Yauh Lee

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background/Aims: The hypothesis that profound acid suppression might prevent clot lysis and thus benefit patients with a non-bleeding visible vessel has not been confirmed. Omeprazole can suppress gastric acid remarkably and may be beneficial for patients with peptic ulcer bleeding. Methodology: Fifty-two patients with a non-bleeding visible vessel at the ulcer base were enrolled and randomized into four groups (N = 13 in each group). In the cimetidine group, the patients received cimetidine 300 mg i.v. bolus followed by 300 mg i.v. every 6 hr during hospitalization. In the heater probe thermocoagulation + cimetidine group, the patients received heater probe thermocoagulation and cimetidine 300 mg i.v. bolus followed by 300 mg i.v. every 6 h during hospitalization. In the omeprazole q.d. group, the patients received omeprazole 40 mg i.v. bolus followed by 40 mg i.v. daily for two days. In the omeprazole q 12 h group, the patients received omeprazole 40 mg i.v. bolus followed by 40 mg i.v., every 12 h for two days. A 24 hr intragastric pH was recorded for every case. Results: The mean 24 hr intragastric pH were higher in the omeprazole q.d. (mean. 5.8) and the omeprazole q 12 h groups (mean 6.4) than in the cimetidine (mean 4.3) and the heater probe thermocoagulation + cimetidine groups (mean 4.9) (p <0.05). Rebleeding occurred in 5, 2, 2 and 2 patients in the cimetidine, heater probe thermocoagulation + cimetidine, omeprazole q.d., and omeprazole q 12h groups, respectively (p > 0.05). Volume of blood transfusion and number of days in hospital were not statistically different among the four groups. Conclusions: Omeprazole can remarkably suppress gastric acid when it is compared to that of the H2 receptor blocker. Patients with a non-bleeding visible vessel using omeprazole do not exhibit a decrease in the rebleeding rate as compared with those patients using cimetidine.

Original languageEnglish
Pages (from-to)1495-1499
Number of pages5
JournalHepato-Gastroenterology
Volume44
Issue number17
Publication statusPublished - 1997
Externally publishedYes

Keywords

  • Acid suppression
  • Non-Bleeding
  • Rebleeding
  • Visible vessel

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Can optimal acid suppression prevent rebleeding in peptic ulcer patients with a non-bleeding visible vessel: A preliminary report of a randomized comparative study'. Together they form a unique fingerprint.

  • Cite this